Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology, Nicotine Addiction and Pain.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H2 2017' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology, Nicotine Addiction and Pain.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
H. Lundbeck AS
NeuroDerm Ltd
Saniona AB
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-9283 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2017: Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
Oct 26, 2017: Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
Oct 04, 2017: Achieve Announces Advancement of Cytisine Clinical Development Program
Aug 16, 2017: Achieve Announces Initiation of Cytisine Clinical Development Program
Aug 10, 2017: Achieve Announces FDA Acceptance of the Investigational New Drug Application for Cytisine as a Smoking Cessation Treatment
May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder
Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ('SRNT')
Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling
Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX (varenicline)
May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet
Sep 04, 2015: Quit-smoking drug safer than thought
Mar 09, 2015: FDA updates label for stop smoking drug Chantix
Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel
Oct 16, 2014: Statement Regarding FDA Advisory Committees’ Vote on CHANTIX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
H. Lundbeck AS
NeuroDerm Ltd
Saniona AB
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-9283 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2017: Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
Oct 26, 2017: Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
Oct 04, 2017: Achieve Announces Advancement of Cytisine Clinical Development Program
Aug 16, 2017: Achieve Announces Initiation of Cytisine Clinical Development Program
Aug 10, 2017: Achieve Announces FDA Acceptance of the Investigational New Drug Application for Cytisine as a Smoking Cessation Treatment
May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder
Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ('SRNT')
Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling
Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX (varenicline)
May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet
Sep 04, 2015: Quit-smoking drug safer than thought
Mar 09, 2015: FDA updates label for stop smoking drug Chantix
Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel
Oct 16, 2014: Statement Regarding FDA Advisory Committees’ Vote on CHANTIX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by H. Lundbeck AS, H2 2017
Pipeline by NeuroDerm Ltd, H2 2017
Pipeline by Saniona AB, H2 2017
Pipeline by Sopharma AD, H2 2017
Pipeline by Suven Life Sciences Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by H. Lundbeck AS, H2 2017
Pipeline by NeuroDerm Ltd, H2 2017
Pipeline by Saniona AB, H2 2017
Pipeline by Sopharma AD, H2 2017
Pipeline by Suven Life Sciences Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
H. Lundbeck AS
NeuroDerm Ltd
Saniona AB
Sopharma AD
Suven Life Sciences Ltd
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
H. Lundbeck AS
NeuroDerm Ltd
Saniona AB
Sopharma AD
Suven Life Sciences Ltd
